1. Home
  2. CTNM vs HIO Comparison

CTNM vs HIO Comparison

Compare CTNM & HIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CTNM
  • HIO
  • Stock Information
  • Founded
  • CTNM 2009
  • HIO 1993
  • Country
  • CTNM United States
  • HIO United States
  • Employees
  • CTNM N/A
  • HIO N/A
  • Industry
  • CTNM
  • HIO Finance/Investors Services
  • Sector
  • CTNM
  • HIO Finance
  • Exchange
  • CTNM Nasdaq
  • HIO Nasdaq
  • Market Cap
  • CTNM 328.1M
  • HIO 368.0M
  • IPO Year
  • CTNM 2024
  • HIO N/A
  • Fundamental
  • Price
  • CTNM $10.90
  • HIO $3.86
  • Analyst Decision
  • CTNM Strong Buy
  • HIO
  • Analyst Count
  • CTNM 5
  • HIO 0
  • Target Price
  • CTNM $22.20
  • HIO N/A
  • AVG Volume (30 Days)
  • CTNM 93.7K
  • HIO 305.3K
  • Earning Date
  • CTNM 11-06-2025
  • HIO 01-01-0001
  • Dividend Yield
  • CTNM N/A
  • HIO 10.33%
  • EPS Growth
  • CTNM N/A
  • HIO N/A
  • EPS
  • CTNM N/A
  • HIO N/A
  • Revenue
  • CTNM N/A
  • HIO N/A
  • Revenue This Year
  • CTNM N/A
  • HIO N/A
  • Revenue Next Year
  • CTNM N/A
  • HIO N/A
  • P/E Ratio
  • CTNM N/A
  • HIO N/A
  • Revenue Growth
  • CTNM N/A
  • HIO N/A
  • 52 Week Low
  • CTNM $3.35
  • HIO $3.52
  • 52 Week High
  • CTNM $20.24
  • HIO $4.03
  • Technical
  • Relative Strength Index (RSI)
  • CTNM 46.91
  • HIO 50.09
  • Support Level
  • CTNM $10.77
  • HIO $3.84
  • Resistance Level
  • CTNM $11.34
  • HIO $3.88
  • Average True Range (ATR)
  • CTNM 0.66
  • HIO 0.04
  • MACD
  • CTNM -0.17
  • HIO 0.01
  • Stochastic Oscillator
  • CTNM 27.31
  • HIO 76.92

About CTNM Contineum Therapeutics Inc. Class A Common Stock

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

About HIO Western Asset High Income Opportunity Fund Inc.

Western Asset High Income Oppor Fd Inc is a diversified closed-end management investment company. The company's primary objective is to seek high current income and the secondary objective is capital appreciation. It invests a majority of its net assets in high-yield corporate debt securities and the rest in common stock equivalents, including options, warrants, and rights. The company invests in securities of companies from various sectors such as energy, technology, utilities, industrials, communications, finance, and capital goods among others.

Share on Social Networks: